Prognostic Significance of Cytokine Release Syndrome in B Cell Hematological Malignancies Patients After Chimeric Antigen Receptor T Cell Therapy

Cytokine release syndrome (CRS) is the most common on-target toxicity of chimeric antigen receptor (CAR) T cell therapy. However, the prognostic significance of CRS has not been well elucidated. The aim of our study was to evaluate the association between CRS and efficacy after anti-CD19 CAR-T therapy in a retrospective cohort of 22 patients with relapsed/refractory B cell hematological malignancies. The complete remission (CR) rates after CAR-T therapy were 68%, and median value for progression-free survival (PFS) was 6.8 months. Eight of 22 (36.4%) patients showed >= grade 2 CRS. Statistical analysis found that patients with >= grade 2 CRS had higher CR rates and longer PFS than those with < grade 2 CRS. Moreover, bridging hematopoietic stem cell transplantation was another independent predictor for PFS. These data suggested that appropriate CRS may be beneficial to the efficacy of CAR-T therapy. The Clinical Trial Registration number is NCT03110640, NCT03302403.

Automated summary

This study evaluated the association between cytokine release syndrome (CRS) and efficacy after anti-CD19 CAR-T therapy in 22 patients with relapsed/refractory B cell hematological malignancies. The findings showed that patients with >= grade 2 CRS had higher complete remission rates (CR) and longer progression-free survival (PFS), and bridging hematopoietic stem cell transplantation was another independent predictor for PFS. The data suggested that appropriate CRS may be beneficial to the efficacy of CAR-T therapy.